Tempus AI, Inc. (NASDAQ:TEM) stock is trading higher on Friday after acquiring Paige, an AI company specializing in digital ...

Tempus AI achieves strong revenue growth and beats expectations, but ongoing losses and execution risks temper enthusiasm.

Tempus AI (TEM) announced on Friday an acquisition of the AI company specializing in digital pathology, Paige, for $81.25M.

Tempus AI’s TEM stock has surged nearly 13% since its second-quarter 2025 earnings release. The quarter saw strong top-line ...

Tempus AI has acquired the digital pathology developer Paige, including its FDA-cleared, artificial intelligence-powered ...

Tempus AI TEM stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 66 to 78. Please ...

Tempus AI shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 88.

It's called Recursion OS. Using 36 petabytes (36 million gigabytes) of biological and chemical data, Recursion OS can ...

In buying Paige, Tempus grows its dataset, expands its tech team and gains a foothold in digital pathology, the company said.

Tempus AI shares were higher after the company said it agreed to buy Paige, an AI company focused on digital pathology, for $81.3 million. The stock was up 8.4% at $83.17 and has more than doubled so ...

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

The stock of Tempus AI (NASDAQ: TEM) gave back some of its gains after surging early in Friday's trading, but it still ended the daily session solidly in the green. The healthcare artificial ...